Related Experiment Video
Updated: Jan 5, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Nivolumab Treatment for the Patients with Gastric Cancer-Present and Future]
Hiroshi Imazeki1, Ken Kato, Narikazu Boku
1Dept. of Gastrointestinal Medical Oncology, National Cancer Center Hospital.
Nivolumab, anti-PD-1 monoclonal antibody, has innovated treatment ofpatients with gastric cancer. Nivolmab has been indicated forBthird-line treatment ofgastric cancer patients in September 2017. Although it has been more than 1 year after nivolumab being widely used in practice, we still have many clinical questions in this population. We leverage evidence obtained from other types of cancer where we have more experience to use nivolumab to answer these questions step by step, but it is still far from enough with some complexities unique to gastric cancer. While nivolumab monotherapy has shown long term survival in some patients, more than halfofpatients experience disease progression right after treatment initiation with nivolumab. Because we have other treatment options, it is urgent to identify biomarkers to predict its efficacy. Now clinical trials ofimmune -checkpoint inhibitors in various treatment line are ongoing with translational research including biomarker analysis and we highly expect those outcome.
Nivolumab, anti-PD-1 monoclonal antibody, has innovated treatment ofpatients with gastric cancer. Nivolmab has been indicated forBthird-line treatment ofgastric cancer patients in September 2017. Although it has been more than 1 year after nivolumab being widely used in practice, we still have many clinical questions in this population. We leverage evidence obtained from other types of cancer where we have more experience to use nivolumab to answer these questions step by step, but it is still far from enough with some complexities unique to gastric cancer. While nivolumab monotherapy has shown long term survival in some patients, more than halfofpatients experience disease progression right after treatment initiation with nivolumab. Because we have other treatment options, it is urgent to identify biomarkers to predict its efficacy. Now clinical trials ofimmune -checkpoint inhibitors in various treatment line are ongoing with translational research including biomarker analysis and we highly expect those outcome.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...